1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
62FEED494103E52DD85257EF8007247FA
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-enabling-marketing-insights-superior-competitiveness-faster-market-research-approvals-managing-cycle-times?opendocument
18
19opendocument
2054.226.58.177
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Market Research, Analytics and Forecasting Process Excellence and Productivity Management

Enabling Marketing Insights and Superior Competitiveness Through Faster Market Research Approvals: Managing Cycle Times

ID: 5384


Features:

16 Info Graphics

15 Data Graphics

200+ Metrics

7 Narratives

8 Best Practices


Pages/Slides: 41


Published: 2015


Delivery Format: Online PDF Document


 

License Options:

close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.

Buy Now

 

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Enabling Marketing Insights and Superior Competitiveness Through Faster Market Research Approvals: Managing Cycle Times"

STUDY OVERVIEW

Timely approvals of market research studies are critical to gain strategic insights that can provide competitive advantage. With different functions, including legal, involved in reviewing proposed market research studies, it is important for biopharmaceutical companies to have an effective and efficient study approval process.


Best Practices, LLC undertook this benchmarking study to investigate how leading companies manage cycle times and produce fast responses to accelerate the market research approval process for quicker and meaningful insights. The study provides benchmarks around length of the approval process for project types, review processing, tracking changes & approvals, response standards, review channels and managing vendors for fast responses.



KEY TOPICS

  • Best Practices of High-Performing Companies
  • Managing Cycle Times & Fast Response
  • Field Interviews & Executive Verbatims


KEY METRICS
  • Market Research Approval Process Times for Different Types of Projects
  • Effectiveness of Different Processes To Manage or Sequence MR Project Proposal Reviews
  • Effective Approaches for Discussing & Ratifying Suggested Changes With Least Amount of Delay
  • Timely Response / Service Level Standards Employed in Market Research Project Approval System
  • Effectiveness of Different Market Research Vendor Management Approaches

SAMPLE KEY FINDINGS
  • Timely Response Standards: Set time and service response standards and close review periods after agreed upon milestones. More than half of Best Practice companies set review periods and while more than 60% enforce stakeholder commitments for compliance, pharmacovigilance and market research. Start by working to consistently develop these exemplary behaviors and discipline with Market Research, Marketing, Compliance, Pharmacovigilance and Ad Promotion. Extend later to Legal (45% companies find this effective), which benchmark field analysis suggests takes longer to accept or develop such review discipline.

METHODOLOGY

Best practices, LLC engaged 22 executives from 21 leading pharmaceutical, biotech, and life sciences companies. Eleven companies responded on behalf of rare disease markets. Eight companies participated in deep-dive interviews about the drivers of operational excellence.


Industries Profiled:
Pharmaceutical; Biotech; Manufacturing; Consumer Products; Diagnostic; Medical Device; Chemical; Health Care; Technology; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Abbvie; actavis; Amgen; AstraZeneca; Bayer; Biogen; Boehringer Ingelheim; CSL Behring; Fresenius Kabi; Genentech; Grifols; Jazz Pharmaceuticals; Lilly; NeedleTech Products Inc.; Novartis; Novo Nordisk; Philips Healthcare; Roche; Sanofi; Teva Pharmaceutical Industries Ltd; UCB Pharma


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.